Timothy J. Vreeland

Timothy J. Vreeland

Auto-generated profile, based on publicly available information

Timothy J. Vreeland

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Journal of Surgical Education
Verified
Journal Article
Closed access
RCRobert Connor Chick
Robert Connor Chick
GCGuy Travis Clifton
Guy Travis Clifton
KPKaitlin M. Peace
Kaitlin M. Peace
BPBrandon W. Propper
Brandon W. Propper
DHDiane F. Hale
Diane F. Hale
TVTimothy J. Vreeland
Timothy J. Vreeland

18 February 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GCG. Travis Clifton
G. Travis Clifton
DHDiane Hale
Diane Hale
TVTimothy J. Vreeland
Timothy J. Vreeland
AHAnnelies T. Hickerson
Annelies T. Hickerson
JLJennifer K. Litton
Jennifer K. Litton
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
Purpose: Preclinical data provide evidence for synergism between HER2-targeted peptide vaccines and trastuzumab. The efficacy of this combination was evaluated in patients with HER2 low-expressing breast cancer in the adjuvant setting. Patients and Methods: A phase IIb, multicenter, randomized, single-blinded, controlled trial enrolled disease-free patients after standard therapy completion (NCT01570036). Eligible patients were HLA-A2, A3, A24, and/or A26+, and had HER2 IHC 1+/2+, FISH nonamplified breast cancer, that was node positive and/or hormone receptor–negative [triple-negative breast cancer (TNBC)]. Patients received trastuzumab for 1 year and were randomized to placebo (GM-CSF, control) or nelipepimut-S (NPS) with GM-CSF. Primary outcome was 24-month disease-free survival (DFS). Secondary outcomes were 36-month DFS, safety, and immunologic response. Results: Overall, 275 patients were randomized; 136 received NPS with GM-CSF, and 139 received placebo with GM-CSF. There were no clinicopathologic differences between groups. Concurrent trastuzumab and NPS with GM-CSF was safe with no additional overall or cardiac toxicity compared with control. At median follow-up of 25.7 (interquartile range, 18.4–32.7) months, estimated DFS did not significantly differ between NPS and control [HR, 0.62; 95% confidence interval (CI), 0.31–1.25; P = 0.18]. In a planned exploratory analysis of patients with TNBC, DFS was improved for NPS versus control (HR, 0.26; 95% CI, 0.08–0.81, P = 0.01). Conclusions: The combination of NPS with trastuzumab is safe. In HER2 low-expressing breast cancer, no significant difference in DFS was seen in the intention-to-treat analysis; however, significant clinical benefit was seen in patients with TNBC. These findings warrant further investigation in a phase III randomized trial.

1 January 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
ANAlexander P. Nissen
Alexander P. Nissen
TVTimothy J. Vreeland
Timothy J. Vreeland
MTMediget Teshome
Mediget Teshome
MAMichael A. Archer
Michael A. Archer
AFAmanda B. Francescatti
Amanda B. Francescatti
TMTimothy W. Mullett
Timothy W. Mullett

27 February 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TVTimothy J. Vreeland
Timothy J. Vreeland
GCGuy T. Clifton
Guy T. Clifton
DHDiane F. Hale
Diane F. Hale
RCRobert C. Chick
Robert C. Chick
AHAnnelies T. Hickerson
Annelies T. Hickerson
MFMark B. Faries
Mark B. Faries

5 July 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TBTommy A. Brown
Tommy A. Brown
KBKevin Byrd
Kevin Byrd
TVTimothy J. Vreeland
Timothy J. Vreeland
GCGuy T. Clifton
Guy T. Clifton
DJDoreen O. Jackson
Doreen O. Jackson
GPGeorge E. Peoples
George E. Peoples
Background: E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to prevent recurrences in disease‐free endometrial and ovarian cancer patients(pts). Here, we present the final 24‐month landmark analysis.Patients and methods: HLA‐A2 + patients receiving E39 + GM‐CSF were included in the vaccine group (VG), and HLA‐A2‐ pts (or HLA‐A2 + patients refusing vaccine) were followed as the control group (CG). VG group received 6 monthly inoculations as the primary vaccine series (PVS) and were randomized to receive either E39 or E39′ booster inoculations. Demographic, safety, immunologic, and disease‐free survival (DFS) data were collected and evaluated.Results: Fifty‐one patients were enrolled; 29 in the VG and 22 in the CG. Fourteen patients received <1000 μg and 15 received 1000 μg of E39. There were no clinicopathologic differences between VG and CG or between dose groups. E39 was well tolerated. At the 24 months landmark, DFS was 55.5% (VG) vs 40.0% (CG), P = 0.339. Patients receiving 1000 μg and boosted patients also showed improved DFS (P < 0.03). DFS was improved in the 1000 μg group after treatment of primary disease (90.0% vs CG:42.9%, P = 0.007), but not in recurrent patients. In low‐FBP expressing patients, DFS was 100.0% (1000 μg), 50.0% (<1000 μg), and 25.0% (CG), P = 0.029.Conclusions: This phase I/IIa trial reveals that E39 + GM‐CSF is safe and may be effective in preventing recurrence in high‐risk ovarian and endometrial cancer when optimally dosed (1000 μg) to FBP low patients being treated for primary disease.

3 August 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ECElizabeth Lee Carpenter
Elizabeth Lee Carpenter
SDSpencer Van Decar
Spencer Van Decar
AAAlexandra M Adams
Alexandra M Adams
AOAnne E O’sHea
Anne E O’sHea
PMPatrick McCarthy
Patrick McCarthy
GPGeorge E Peoples
George E Peoples
Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded YCWPs coated with silicate for in vivo DC loading. Here we report the 36-month prespecified analyses of this prospective, randomized, double-blind trial investigating the ability of the TLPO and TLPLDC (±granulocyte-colony stimulating factor (G-CSF)) vaccines to prevent melanoma recurrence in high-risk patients. Methods Patients with clinically disease-free stage III/IV melanoma were randomized 2:1 initially to TLPLDC versus placebo (n=124) and subsequently TLPO versus TLPLDC (n=63). All patients were randomized and blinded; however, the placebo control arm was replaced in the second randomization scheme with another novel vaccine; some analyses in this paper therefore reflect a combination of the two randomization schemes. Patients receiving the TLPLDC vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment); this was not randomized. The use of standard of care checkpoint inhibitors was not stratified between groups. Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS). Results After combining the two randomization processes, a total of 187 patients were allocated between treatment arms: placebo (n=41), TLPLDC (n=103), or TLPO (n=43). The allocation among arms created by the addition of patients from the two separate randomization schemes does not reflect concurrent randomization among all treatment arms. TLPLDC was further divided by use of G-CSF in DC harvest: no G-CSF (TLPLDC) (n=47) and with G-CSF (TLPLDC+G) (n=56). Median follow-up was 35.8 months. Only two patients experienced a related adverse event ≥grade 3, one each in the TLPLDC+G and placebo arms. DFS was 27.2% (placebo), 55.4% (TLPLDC), 22.9% (TLPLDC+G), and 60.9% (TLPO) (p<0.001). OS was 62.5% (placebo), 93.6% (TLPLDC), 57.7% (TLPLDC+G), and 94.6% (TLPO) (p=0.002). Conclusions The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial. Trial registration number NCT02301611.